Europe
Biopharma and life sciences organizations strengthen their leadership teams and board with these Movers & Shakers.
Sanofi’s experimental breast cancer treatment amcenestrant in combination with Pfizer’s Ibrance is showing promising anti-tumor activity in postmenopausal women with metastatic breast cancer.
The new vaccination, dubbed VAXELIS, is indicated for active immunization to help prevent diphtheria, tetanus, pertussis, poliomyelitis, hepatitis B, and invasive disease due to Haemophilus influenzae type b.
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
Calliditas is developing Nefecon, a down regulator of IgA1 and proprietary, novel oral formulation of budesonide – a potent and established immunosuppressant – for the treatment of IgAN.
Inclusions and treatment initiation will be paused in all ongoing clinical studies until an investigation into the potential safety issue is complete.
There were seven initial public offerings (IPOs) for biotech companies in the month of May. Here’s a look.
The early termination of the Beovu trials places a damper on Novartis’ hopes of competing even further with Regeneron Pharmaceuticals’ retinal disease drug Eylea.
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.
PRESS RELEASES